Efficacy and Safety of Pertuzumab and Trastuzumab Administered in a Single Infusion Bag, Followed by Vinorelbine: VELVET Cohort 2 Final Results.

Date publication

juin 2017

Journal

The oncologist

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PETIT Thierry

Tous les auteurs :
Andersson M, López-Vega JM, Petit T, Zamagni C, Easton V, Kamber J, Restuccia E, Perez EA

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/28592618

Résumé

VELVET Cohort 1 demonstrated the applicability of pertuzumab, trastuzumab, and vinorelbine as an alternative first-line treatment regimen for patients with HER2-positive locally advanced or metastatic breast cancer (MBC) who cannot receive docetaxel. Co-infusion of pertuzumab and trastuzumab may reduce clinic time and medical resource utilization. We report results from Cohort 2, in which pertuzumab and trastuzumab were co-infused, followed by vinorelbine.

Mots clés

HER2-positive, Metastatic breast cancer, Pertuzumab, Trastuzumab, Vinorelbine

Référence

Oncologist. 2017 Jun;: